New biosimilar for fabry disease shows promise in small switch trial
Disease control
Completed
This study tested a new enzyme replacement drug (AGA BETA BS) in 20 adults with Fabry disease who were already stable on the standard treatment, Fabrazyme. The goal was to see if switching to the new drug kept their disease marker (Lyso-Gb3) at similar levels over 6 months. The t…
Phase: PHASE3 • Sponsor: Bio Sidus SA • Aim: Disease control
Last updated May 01, 2026 15:56 UTC